At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
INCB024360drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Determine the Safety and Efficacy of INCB024360 in Patients With Myelodysplastic Syndromes
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Apr 2, 2013·Updated Jan 18, 2016
In Brief
A Phase 2 clinical trial evaluating INCB024360 for Myelodysplastic Syndromes. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The primary purpose of this research study is to assess whether the participant's disease, Myelodysplastic Syndromes (MDS), responds favorably to INCB024360. The study will also evaluate the long-term outcomes of the participant's disease after they have finished taking INCB024360.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJul 2013
Primary CompletionJan 2015
Study CompletionFeb 2015
TodayJul 2026
First PostedApr 2, 2013
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2015
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.3 years ago
Interventions
INCB024360drug
INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.